. Author manuscript; available in PMC: 2011 Mar 30.

Published in final edited form as: Oncogene. 2010 Jul 19;29(39):5359–5369. doi: 10.1038/onc.2010.274

Table 1.

Tumor incidence in females of two NRL-PRL transgenic lines that are conditionally deficient in Jak2 (MMTV-Cre Jak2^fl/fl) and their littermate controls expressing Jak2 (Jak2^fl/fl).

Genotype	Number of females	Incidence of proliferative lesions
Genotype	Number of females	Mammary Tumors	Atypical Hyperplasia	Total
Total
Jak2^fl/fl	59	16 (27.1 %)	20 (33.9 %)	36 (61.0 %)
MMTV-Cre Jak2^fl/fl	28	0	2 (7.1 %)	2 (7.1 %)

NRL-PRL (line 1647-13)
Jak2^fl/fl	32	7 (21.9 %)	13 (40.6 %)	20 (62.5 %)
MMTV-Cre Jak2^fl/fl	14	0	0	0
NRL-PRL (line 1655-8)
Jak2^fl/fl	27	9 (33.3 %)	7 (25.9 %)	16 (59.3 %)
MMTV-Cre Jak2^fl/fl	14	0	2 (14.3 %)	2 (14.3 %)